Clinical Trials · NCT07417618
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
- Phase
- N/A
- Recruitment status
- Active Not Recruiting
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 60,000
- Start date
- Jan 2026
- Locations
- 1 site, United States
- Primary endpoint
- Composite of myocardial infarction, stroke, or all-cause mortality (with ASCVD)